Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Forschende Komplementarmedizin (2006)
|
April 4, 2006
[Tibetan medicine in Europe: historical, practical and regulatory aspects]
Herbert Schwabl, Susanne Geistlich, Elisabeth McHugh
Molecules (Basel, Switzerland)
|
February 26, 2020
A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with <sup>68</sup>Ga, <sup>44</sup>Sc, <sup>177</sup>Lu and <sup>161</sup>Tb
Zeynep Talip, Chiara Favaretto, Susanne Geistlich, et al.
Chimia
|
December 28, 2020
Targeted Radiotherapeutics from 'Bench-to-Bedside'
Cristina Müller, Martin Béhé, Susanne Geistlich, et al.
Chimia
|
December 28, 2020
Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System
Linjing Mu, Stefanie D Krämer, Hazem Ahmed, et al.
EJNMMI Research
|
June 27, 2019
Radiation dosimetry of [<sup>18</sup>F]-PSS232-a PET radioligand for imaging mGlu5 receptors in humans
Bert-Ram Sah, Michael Sommerauer, Linjing Mu, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 28, 2017
A first-in-man PET study of [<sup>18</sup>F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5
Geoffrey Warnock, Michael Sommerauer, Linjing Mu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 18, 2023
<sup>161</sup>Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of <sup>161</sup>Tb into the Clinic
Chiara Favaretto, Pascal V Grundler, Zeynep Talip, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 14, 2018
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog <sup>177</sup>Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Alexander W Sauter, Rosalba Mansi, Ulrich Hassiepen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 15, 2019
Cholecystokinin 2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
EJNMMI Research
|
April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study
Christof Rottenburger, Michael Hentschel, Markus Fürstner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Forschende Komplementarmedizin (2006)
|
April 4, 2006
[Tibetan medicine in Europe: historical, practical and regulatory aspects]
Herbert Schwabl, Susanne Geistlich, Elisabeth McHugh
Molecules (Basel, Switzerland)
|
February 26, 2020
A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with <sup>68</sup>Ga, <sup>44</sup>Sc, <sup>177</sup>Lu and <sup>161</sup>Tb
Zeynep Talip, Chiara Favaretto, Susanne Geistlich, et al.
Chimia
|
December 28, 2020
Targeted Radiotherapeutics from 'Bench-to-Bedside'
Cristina Müller, Martin Béhé, Susanne Geistlich, et al.
Chimia
|
December 28, 2020
Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System
Linjing Mu, Stefanie D Krämer, Hazem Ahmed, et al.
EJNMMI Research
|
June 27, 2019
Radiation dosimetry of [<sup>18</sup>F]-PSS232-a PET radioligand for imaging mGlu5 receptors in humans
Bert-Ram Sah, Michael Sommerauer, Linjing Mu, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 28, 2017
A first-in-man PET study of [<sup>18</sup>F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5
Geoffrey Warnock, Michael Sommerauer, Linjing Mu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 18, 2023
<sup>161</sup>Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of <sup>161</sup>Tb into the Clinic
Chiara Favaretto, Pascal V Grundler, Zeynep Talip, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 14, 2018
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog <sup>177</sup>Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Alexander W Sauter, Rosalba Mansi, Ulrich Hassiepen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 15, 2019
Cholecystokinin 2 Receptor Agonist <sup>177</sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
EJNMMI Research
|
April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [<sup>177</sup>Lu]Lu-PP-F11N in humans: the lumed phase 0b study
Christof Rottenburger, Michael Hentschel, Markus Fürstner, et al.
Page
of 2